Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 4/2023

Open Access 07-04-2023 | Insulinoma | Case Report

Combined tubular adenocarcinoma, neuroendocrine carcinoma and adenocarcinoma with enteroblastic differentiation arising in Barrett esophagus

Authors: Kotaro Sugawara, Takashi Fukuda, Yutaka Kishimoto, Daiji Oka, Yoshiyuki Kawashima, Naoko Inoshita, Hiroaki Kanda

Published in: Clinical Journal of Gastroenterology | Issue 4/2023

Login to get access

Abstract

Adenocarcinoma (AC) with neuroendocrine carcinoma (NEC) or enteroblastic (ENT) differentiation rarely develops in Barrett’s esophagus (BE). A 76-year-old man was diagnosed with Barrett’s AC (cT1bN0M0) and underwent thoracoscopic esophagectomy. A type 0-IIc + 0-Is lesion measuring 26 × 21 mm was macroscopically observed on a background of long segment BE (pT1bN0M0). The tumor comprised three different histological types of carcinoma (NEC, AC with ENT differentiation and moderately differentiated AC). NEC showed positivity for synaptophysin, chromogranin A and insulinoma-associated protein 1 with a Ki-67 index of 60.6%. ENT tumors were immunopositive for AFP and sal-like protein 4, and focally immunopositive for human chorionic gonadotrophin. The amounts of NEC, ENT and AC were 40%, 40% and 20%, respectively. p53 expression was positive throughout the tumor. Rb expression was negative at the NEC, but positive at the ENT and AC. CD4 and CD8 densities were lower in the NEC segment than in the AC and ENT segments, and PD-L1 expression was negative throughout the tumor. Early cancer arising in BE with a combination of tubular AC, ENT tumors and NEC is very rare. Our observations might contribute to understanding the carcinogenetic pathways and tumor microenvironment of NEC and ENT tumors.
Appendix
Available only for authorised users
Literature
2.
go back to reference van Munster SN, Verheij EPD, Nieuwenhuis EA, et al. Extending treatment criteria for Barrett’s neoplasia: results of a nationwide cohort of 138 endoscopic submucosal dissection procedures. Endoscopy. 2022;54:531–41.CrossRefPubMed van Munster SN, Verheij EPD, Nieuwenhuis EA, et al. Extending treatment criteria for Barrett’s neoplasia: results of a nationwide cohort of 138 endoscopic submucosal dissection procedures. Endoscopy. 2022;54:531–41.CrossRefPubMed
3.
go back to reference Kinoshita T, Ishikawa S, Inaba T, et al. Neuroendocrine carcinoma arising from Barrett’s esophageal adenocarcinoma: a case report. Clin J Gastroenterol. 2020;13:1028–35.CrossRefPubMed Kinoshita T, Ishikawa S, Inaba T, et al. Neuroendocrine carcinoma arising from Barrett’s esophageal adenocarcinoma: a case report. Clin J Gastroenterol. 2020;13:1028–35.CrossRefPubMed
4.
go back to reference Kawazoe T, Saeki H, Edahiro K, et al. A case of mixed adenoneuroendocrine carcinoma (MANEC) arising in Barrett’s esophagus: literature and review. Surg Case Rep. 2018;4:45.CrossRefPubMedPubMedCentral Kawazoe T, Saeki H, Edahiro K, et al. A case of mixed adenoneuroendocrine carcinoma (MANEC) arising in Barrett’s esophagus: literature and review. Surg Case Rep. 2018;4:45.CrossRefPubMedPubMedCentral
5.
go back to reference Motoyama T, Higuchi M, Taguchi J. Combined choriocarcinoma, hepatoid adenocarcinoma, small cell carcinoma and tubular adenocarcinoma in the oesophagus. Virchows Arch. 1995;427:451–4.CrossRefPubMed Motoyama T, Higuchi M, Taguchi J. Combined choriocarcinoma, hepatoid adenocarcinoma, small cell carcinoma and tubular adenocarcinoma in the oesophagus. Virchows Arch. 1995;427:451–4.CrossRefPubMed
6.
go back to reference Murakami T, Yao T, Mitomi H, et al. Clinicopathologic and immunohistochemical characteristics of gastric adenocarcinoma with enteroblastic differentiation: a study of 29 cases. Gastric Cancer. 2016;19:498–507.CrossRefPubMed Murakami T, Yao T, Mitomi H, et al. Clinicopathologic and immunohistochemical characteristics of gastric adenocarcinoma with enteroblastic differentiation: a study of 29 cases. Gastric Cancer. 2016;19:498–507.CrossRefPubMed
7.
go back to reference Maru DM, Khurana H, Rashid A, et al. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008;32:1404–11.CrossRefPubMed Maru DM, Khurana H, Rashid A, et al. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008;32:1404–11.CrossRefPubMed
8.
go back to reference Yamashita S, Abe H, Kunita A, et al. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma. Histopathology. 2021;78:381–91.CrossRefPubMed Yamashita S, Abe H, Kunita A, et al. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma. Histopathology. 2021;78:381–91.CrossRefPubMed
9.
go back to reference Brierley JD, Gospodarowicz MK, Wittekind C, editors. The TNM classification of malignant tumours. 8th ed. Oxford: Wiley Blackwell; 2017. Brierley JD, Gospodarowicz MK, Wittekind C, editors. The TNM classification of malignant tumours. 8th ed. Oxford: Wiley Blackwell; 2017.
10.
go back to reference Mitsuma K, Taniguchi H, Kishi Y, et al. A case of adenocarcinoma with enteroblastic differentiation of the ampulla of Vater. Pathol Int. 2016;66:230–5.CrossRefPubMed Mitsuma K, Taniguchi H, Kishi Y, et al. A case of adenocarcinoma with enteroblastic differentiation of the ampulla of Vater. Pathol Int. 2016;66:230–5.CrossRefPubMed
11.
go back to reference Takubo K, Vieth M, Aida J, et al. Histopathological diagnosis of adenocarcinoma in Barrett’s esophagus. Dig Endosc. 2014;26:322–30.CrossRefPubMed Takubo K, Vieth M, Aida J, et al. Histopathological diagnosis of adenocarcinoma in Barrett’s esophagus. Dig Endosc. 2014;26:322–30.CrossRefPubMed
12.
go back to reference Aida J, Vieth M, Shepherd NA, et al. Is carcinoma in columnar-lined esophagus always located adjacent to intestinal metaplasia? A histopathologic assessment. Am J Surg Pathol. 2015;39:188–96.CrossRefPubMed Aida J, Vieth M, Shepherd NA, et al. Is carcinoma in columnar-lined esophagus always located adjacent to intestinal metaplasia? A histopathologic assessment. Am J Surg Pathol. 2015;39:188–96.CrossRefPubMed
13.
go back to reference Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2010. Esophagus: Off J Jpn Esophageal Soc. 2017;14:189–214.CrossRef Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2010. Esophagus: Off J Jpn Esophageal Soc. 2017;14:189–214.CrossRef
14.
go back to reference Board WCTE. WHO classification of tumours. Digestive system tumours: WHO classification of tumours, vol. 1. World Health Organization; 2019. Board WCTE. WHO classification of tumours. Digestive system tumours: WHO classification of tumours, vol. 1. World Health Organization; 2019.
15.
go back to reference Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33:115–54.CrossRefPubMed Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33:115–54.CrossRefPubMed
16.
go back to reference González I, Lu HC, Sninsky J, et al. Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts. Histopathology. 2019;75:568–77.CrossRefPubMed González I, Lu HC, Sninsky J, et al. Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts. Histopathology. 2019;75:568–77.CrossRefPubMed
17.
go back to reference Kinjo T, Taniguchi H, Kushima R, et al. Histologic and immunohistochemical analyses of α-fetoprotein–producing cancer of the stomach. Am J Surg Pathol. 2012;36:56–65.CrossRefPubMed Kinjo T, Taniguchi H, Kushima R, et al. Histologic and immunohistochemical analyses of α-fetoprotein–producing cancer of the stomach. Am J Surg Pathol. 2012;36:56–65.CrossRefPubMed
18.
go back to reference Busse A, Mochmann LH, Spenke C, et al. Immunoprofiling in neuroendocrine neoplasms unveil immunosuppressive microenvironment. Cancers (Basel). 2020;12:3448.CrossRefPubMed Busse A, Mochmann LH, Spenke C, et al. Immunoprofiling in neuroendocrine neoplasms unveil immunosuppressive microenvironment. Cancers (Basel). 2020;12:3448.CrossRefPubMed
19.
go back to reference La Rosa S, Vanoli A. Gastric neuroendocrine neoplasms and related precursor lesions. J Clin Pathol. 2014;67:938–48.CrossRefPubMed La Rosa S, Vanoli A. Gastric neuroendocrine neoplasms and related precursor lesions. J Clin Pathol. 2014;67:938–48.CrossRefPubMed
20.
go back to reference Yachida S, Totoki Y, Noë M, et al. Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system. Cancer Discov. 2022;12:692–711.CrossRefPubMedPubMedCentral Yachida S, Totoki Y, Noë M, et al. Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system. Cancer Discov. 2022;12:692–711.CrossRefPubMedPubMedCentral
21.
go back to reference Kumashiro Y, Yao T, Aishima S, et al. Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype. Hum Pathol. 2007;38:857–63.CrossRefPubMed Kumashiro Y, Yao T, Aishima S, et al. Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype. Hum Pathol. 2007;38:857–63.CrossRefPubMed
22.
go back to reference Akiyama S, Tamura G, Endoh Y, et al. Histogenesis of hepatoid adenocarcinoma of the stomach: molecular evidence of identical origin with coexistent tubular adenocarcinoma. Int J Cancer. 2003;106:510–5.CrossRefPubMed Akiyama S, Tamura G, Endoh Y, et al. Histogenesis of hepatoid adenocarcinoma of the stomach: molecular evidence of identical origin with coexistent tubular adenocarcinoma. Int J Cancer. 2003;106:510–5.CrossRefPubMed
23.
go back to reference Kimura T, Hikichi T, Nakamura J, et al. Gastric adenocarcinoma with enteroblastic differentiation followed endoscopically: a case report. Clin J Gastroenterol. 2020;13:1074–82.CrossRefPubMed Kimura T, Hikichi T, Nakamura J, et al. Gastric adenocarcinoma with enteroblastic differentiation followed endoscopically: a case report. Clin J Gastroenterol. 2020;13:1074–82.CrossRefPubMed
24.
go back to reference Wang J, Liu W, Parikh K, et al. Alpha-fetoprotein-producing esophageal adenocarcinoma: a mimicker of hepatocellular carcinoma. Clin J Gastroenterol. 2017;10:7–12.CrossRefPubMed Wang J, Liu W, Parikh K, et al. Alpha-fetoprotein-producing esophageal adenocarcinoma: a mimicker of hepatocellular carcinoma. Clin J Gastroenterol. 2017;10:7–12.CrossRefPubMed
Metadata
Title
Combined tubular adenocarcinoma, neuroendocrine carcinoma and adenocarcinoma with enteroblastic differentiation arising in Barrett esophagus
Authors
Kotaro Sugawara
Takashi Fukuda
Yutaka Kishimoto
Daiji Oka
Yoshiyuki Kawashima
Naoko Inoshita
Hiroaki Kanda
Publication date
07-04-2023
Publisher
Springer Nature Singapore
Published in
Clinical Journal of Gastroenterology / Issue 4/2023
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-023-01791-0

Other articles of this Issue 4/2023

Clinical Journal of Gastroenterology 4/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.